NCT01808885View on ClinicalTrials.gov

Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

olesoxime (TRO19622)

"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."

DRUG

placebo

placebo capsule shells with identical appearance as the active compound TRO19622

Trial Locations (3)

13385

Timone University Hospital, Neurology Department, UMR CRMBM CNRS 6612, Marseille

35033

CHU Pontchaillou, Neurology Department, Rennes

51092

CHU Reims, Maison Blanche Hospital, Neurology Department & University of Reims, Reims

All Listed Sponsors
collaborator

Hôpital de la Timone

OTHER

collaborator

SGS S.A.

INDUSTRY

collaborator

STRAGEN Services

UNKNOWN

lead

Hoffmann-La Roche

INDUSTRY

NCT01808885 - Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. | Biotech Hunter | Biotech Hunter